[The clinical and pathological features, biomarker characteristics and prognosis analysis of lung adenosquamous carcinoma].

Zhou, S Y; Xue, Q; Ying, J M; Hu, X S; Yang, J L; Lin, H; Shi, Y K

Zhou, S Y; Xue, Q; Ying, J M; Hu, X S; Yang, J L; Lin, H; Shi, Y K.

Afiliação

Zhou SY; Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Xue Q; Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Ying JM; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Hu XS; Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Yang JL; Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Lin H; Outpatient Medical Records Room, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Shi YK; Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Zhonghua Zhong Liu Za Zhi ; 41(1): 50-55, 2019 Jan 23.

Article em Zh | MEDLINE | ID: mdl-30678417

Assuntos

Adenocarcinoma; Carcinoma Adenoescamoso; Carcinoma de Células Escamosas; Neoplasias Pulmonares; Adenocarcinoma/genética; Adenocarcinoma/mortalidade; Adenocarcinoma/patologia; Biomarcadores Tumorais; Carcinoma Adenoescamoso/genética; Carcinoma Adenoescamoso/mortalidade; Carcinoma Adenoescamoso/patologia; Carcinoma de Células Escamosas/genética; Carcinoma de Células Escamosas/mortalidade; Carcinoma de Células Escamosas/patologia; Receptores ErbB/genética; Humanos; Neoplasias Pulmonares/genética; Neoplasias Pulmonares/mortalidade; Neoplasias Pulmonares/patologia; Mutação; Estadiamento de Neoplasias; Prognóstico; Estudos Retrospectivos; Taxa de Sobrevida

Palavras-chave

Drive mutation; EGFR; Lung adenosquamous carcinoma; Prognosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Adenocarcinoma / Carcinoma Adenoescamoso / Neoplasias Pulmonares Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans Idioma: Zh Revista: Zhonghua Zhong Liu Za Zhi Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google